**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April. The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$791,987 Vol.
31 mar 2026
30 de setembro
14%
31 de dezembro
28%
$791,987 Vol.
30 de setembro
$0 Vol.
14%
31 de dezembro
$182,416 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April.
The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Volume
$791,987Data de Término
31 mar 2026Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April.
The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$791,987Data de Término
31 mar 2026Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April. The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions